drugset
drugset / Trial / NCT06181786

Study of NAV-240 in Healthy Volunteers

NCT06181786 ↗

Phase 1 Completed 40 enrolled Navigator Medicines, Inc. IMBiologics Corp. · collab
RandomizedSequentialQuadruple-blindBasic science

Summary

The primary purpose of this study is to evaluate the safety and tolerability of intravenous (IV) doses of NAV-240 in healthy volunteers.

Timeline

Start
2023-11-22
Primary completion
2024-09-04
Completion
2024-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject NAV-240 Unknown — Intravenous

Indications

No indication recorded.